We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




Simple Method Developed to Characterize Immune Cells in Tumors

By LabMedica International staff writers
Posted on 27 Jul 2016
Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them and therefore predictive markers of disease course and response to immunotherapy are urgently needed.

A new method has been developed for analyzing multiple tissue markers using only one slide of a tumor section to better understand immune response occurring locally. More...
The multiplexed immunohistochemical consecutive staining on a single slide (MICSSS) helps characterize human cells involved in immune responses at the tissue site, before and after treatment with immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their international colleagues obtained paraffin-embedded human tonsils, ulcerative colitis, non-small cell lung cancer (NSCLC), melanoma, and colorectal tumor samples from their Biorepository tissue bank. The formalin-fixed paraffin embedded (FFPE) were processed for immunohistochemistry (IHC) and images were acquired using an Olympus whole-slide scanner with OlyVIA software (Olympus Life Science, Center Valley, PA, USA) or an Eclipse Ci-E microscope (Nikon Instruments, Melville, NY, USA).

The authors have described a multiplexed chromogenic IHC strategy for high-dimensional tissue analysis that circumvents many of the limitations of regular chromogenic, immunofluorescence, and mass cytometry approaches that could be readily implemented in clinical pathology laboratories. The MICSSS method provides a new powerful tool to map the microenvironment of tissue lesional sites with excellent resolution, in a sample-sparing manner, to monitor immune changes in situ during therapy and help identify prognostic and predictive markers of clinical outcome in patients with cancer and inflammatory diseases.

Sacha Gnjatic, PhD, an Associate Professor and senior co-author said, “Our goal was to get a better understanding of immunologic responses at the tumor site while addressing the need for high-dimensional analysis using as little tissue as possible. We need more comprehensive analyses of the immune microenvironment of tumors, as part of our immune monitoring to inform treatment and predict outcomes for cancer patients.” The study was published on July 14, 2016, in the journal Science Immunology.

Related Links:
Icahn School of Medicine at Mount Sinai
Olympus Life Science
Nikon Instruments

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.